Market Update (NYSE:MRK): FDA panel rejects Merck claim Zetia/Vytorin cut heart risk

[Reuters] – Merck & Co should not be allowed to claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease, an . . . → Read More: Market Update (NYSE:MRK): FDA panel rejects Merck claim Zetia/Vytorin cut heart risk Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – Panel recommends Merck & Co continue cholesterol drug study Stock Update (NYSE:MRK): Panel recommends Merck & Co continue cholesterol drug study Market Update: Merck & Co Inc (NYSE:MRK) – Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS